Drug Profile
Cantharidin - Verrica Pharmaceuticals
Alternative Names: Cantharidin 0.7% topical solution; TO-208; VP 102 - Verrica Pharmaceuticals; VP 103; VP 103 - Verrica Pharmaceuticals; VP-102; YCANTHLatest Information Update: 08 Feb 2024
Price :
$50
*
At a glance
- Originator Verrica Pharmaceuticals
- Developer Torii Pharmaceutical; Verrica Pharmaceuticals
- Class Antivirals; Benzofurans; Epoxy compounds; Skin disorder therapies; Small molecules
- Mechanism of Action Serine protease stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Molluscum contagiosum
- Phase II Genital warts; Warts
Most Recent Events
- 05 Feb 2024 Verrica Pharmaceuticals files lawsuit against Dormer Laboratories for false advertising and unfair competition
- 04 Jan 2024 Verrica Pharmaceuticals receives minutes of type C meeting held with the US FDA to discuss the Phase III clinical development plan for Cantharidin (YCANTH) for the treatment of common warts
- 15 Dec 2023 Efficacy and adverse events data from phase III clinical trials in Molluscum contagiosum released by Verrica Pharmaceuticals